Supplemental Online Materials

1.	INDIVIDUAL PARTICIPANT DATA AND ANALYSIS PLAN	2
2.	DESCRIPTIVE STATISTICS AND RISK OF BIAS ASSESSMENT	16
3.	MODEL DEVELOPMENT AND APPARENT PERFORMANCE	28
4.	INTERNAL-EXTERNAL CROSS VALIDATION (IECV)	34
5.	SENSITIVITY ANALYSIS	39
6.	SECONDARY ANALYSES	44

1. Individual participant data and analysis plan

Study	Ν	Study type	Inclusion	Length of	Follow	Mean age	Gender (%	RCT	Duration of
			criteria	Follow-up	up	(SD)	Female)	Intervention	RCT
					Points				Intervention
CADET	581	RCT	Adults with	12 months	0, 4,12	44.4 (13.3)	71.9	Collaborative	14 weeks
			depression					care	
CASPER	485	RCT	65 years	18 months	0, 4, 12	Intervention	Intervention	Collaborative	8-10 weeks
Plus	(358		or older		and 18	group: 71.9	group: 59.1	care	
	at		with		months	(6.03)			
	12		depression				Control:		
	m)					Control:	63.1		
						71.6 (5.96)			
COBRA	440	RCT	Adults with	18 months	0, 6,	43.5 (14.1)	66	Behavioural	16 weeks
			depression		12, 18			Activation vs	
								CBT	
Healthlines	609	RCT	Adults with	12 months	0,	Intervention	Intervention	Complex	12 months
Depression			depression		4,8,12	group: 49.1	group: 69	intervention	
						(12.9)	Control: 68	(Integrated	
								telehealth)	
						Control: 50			
						(12.8)			

Table 1.1: Sources of individual participant data

REEACT	461	RCT	Adults with	24 months	0, 4, 12	39.86	67	cCBT	6 weeks
			depression		and 24	(12.65)			
					months				
REEACT-2	369	RCT	Adults with	12 months.	0, 4	40.6 (13.8)	64.5	cCBT	4 months
			depression		and 12				
					months				
WYLOW	439	Longitudinal	Adults with	12 months	Monthly	41.28	59.7	None (cohort	NA
		observational	depression	(Start-point		(14.59)		were	
		cohort study		=				followed up	
				Remission)				after LiCBT)	

ltem	Description	Score
Compulsions	A series of questions around compulsions	+1 if repeating actions >3 days in past week +1 if attempted to stop +1 if action is upsetting +1 if an action was repeated more than twice
Anxiety	A series of questions around anxiety	+1 if anxious for >3days in past week +1 if causes feeling of unpleasantness +1 if causes physical symptoms +1 if anxious >3hrs in any day
Irritability	A series of questions around feelings of irritability, anger or short-temper	 +1 if consistent during the past week (>3 days) +1 if feeling lasted >1hr in any day during past week +1 if shouted or felt like shouting +1 if lost temper without reason
Worry	A series of questions around worry	 +1 if worry persists for >3days in past week +1 if excessively worried +1 if worry was unpleasant +1 if worried >3hrs in any day
Panic	A series of questions around panic	 +1 if panic occurred once in past week +1 if panic occurred at least once more in past week +1 if panic attack lasted longer than 10 mins +1 if panic attack was unpleasant
Phobias	A series of questions around phobias	 +1 if anxious for >3days in past week +1 if causes physical symptoms +1 if avoidance action taken for at least 1day +1 if avoidance action taken for more than 3days
Obsessions	A series of questions around the presence of obsessive thoughts	 +1 if consistent during the past week (>3 days) +1 if tried to stop +1 if they are upsetting +1 lasted for at least 15 mins
Health anxiety	A series of questions about concern over health or future health	 +1 if consistent during the past week (>3 days) +1 if considered excessive +1 if considered unpleasant +1 if difficult to stop worrying
Somatic concerns	A series of questions around the presence	+1 if consistent during the past week (>3 days).

Table 1.2: CIS-R anxiety subscale

of aches/pains or bodily discomfort	 +1 if consistent and lasted at least 3 in any day during last week +1 if consistent and unpleasant +1 if consistent and bothersome during 'interesting' activity
	'interesting' activity

Variable	Original categories (in RCTs)	New categories
		(PREDICTR)
Ethnicity	White	White
	Mixed	Other
	Black	
	Asian	
	Chinese	
	Other	
Employment	Employed (Full time or part time)	Employed/not
status	Student	seeking
	Retired	employment
	House-person	
	Unemployed due to ill-health	
	Other	
	Unemployed and seeking work	Unemployed
Relationship	Married/civil	In a relationship
status	partnership/cohabiting/relationship	
	Single	Single
	Separated	
	Divorced	
	Widowed	
Multimorbidity	None	No long-term
	Mental health only	physical health
		condition
	Diabetes	One or more long-
	Asthma or COPD	term physical
	Degenerative or inflammatory	health conditions
	arthritis	
	Heart Disease	
	Stroke	
	Cancer	

Table 1 2	Po estagorization	of actogorical	variables fo	r analycia
		UI Calegunical		i anaiysis

Code	Description of code	Type of data	Method of measurement	Range of values and coding of predictors
ID_orig	ID in original study	Identifier (individual participant)	NA	NA
ID_PREDICTR	ID assigned for purpose of PREDICTR IPD dataset	Identifier (individual participant)	NA	NA
RCT	Coding for individual studies	Identifier (cluster)	NA	CADET=1 CASPER Plus=2 COBRA=3 Healthlines=4 REEACT=5 REEACT-2=6 WYLOW=7
PHQ_baseline	PHQ-9 at Baseline of RCT	Continuous	PHQ-9	0-27
GAD_baseline	GAD-7 at baseline	Continuous	GAD-7	0-21
PHQ_FU1	t=0 for PREDICTR	Continuous	PHQ-9	0-27

Table 1.4: Master codebook for IPD Harmonisation

PHQ_FU2	6-8 months post-FU1	Continuous	PHQ-9	0-27
followup_time_(FU2- FU1)	How long has elapsed between FU1 and FU2	NA	NA	6 or 8 (months)
remit	Has the pt remitted at FU1? If PHQ-9 score at baseline > 10 and less than 10 at FU1 (plus change of 5 or more points)	Binary	NA	Yes=1, No=0
relapse	Has the pt relapsed at FU2? If remission at FU1 and PHQ-9 >10 (plus change of 5 or more points)	Binary	NA	Yes=1, No=0
residual_symptoms (=PHQ_FU1)	PHQ-9 at remission	Continuous	PHQ-9 score at remission	0-9

prev_eps	Number of previous episodes of depression	Categorical	Patient or GP report (No previous episodes vs any previous episodes)	No previous episodes=0; 1 or more previous episodes=1
comorbid_anx (=GAD_baseline)	Comorbid anxiety	Continuous	GAD-7 Score	0-21
comorbid_anx_zscore	Comorbid anxiety (z score)	Continuous	Combined z score based on mean and SD within original study dataset GAD-7 for all studies other than REEACT For REEACT, z score of CIS-R anxiety subscale	NA
Severity (=PHQ_baseline)	Severity of depression at baseline	Continuous	PHQ-9 score at baseline	10-27
RCT_intervention	Presence or absence of	Categorical	Presence or absence of treatment	Absence of effective treatment

	RCT intervention			(control arm or non-effective intervention)=0; Presence of treatment (effective intervention arm)=1
age	Age in years	Continuous	Self-report	
gender	Gender	Categorical	Self-report	Male=0, Female=1
ethnicity	Ethnicity	Categorical	Self-report	White=0 Other=1
employment	Employment status	Categorical	Self-report	Unemployed=0; Employed=1
relationship	Relationship status	Categorical	Self-report	In a relationship=1; Not in a relationship=0
multi_morbidity	Multi-morbidity	Categorical	Self-report	No long-term physical health condition=0; One or more long-term physical health conditions=1
ADM_current	Current antidepressant	Categorical	Self-report	Not currently taking ADM at remission=0;

medication		Taking ADM at
(ADM)		remission=1



Figure 1.1: Flow diagram of participants in PREDICTR dataset

1.1. Changes from protocol

The full protocol and statistical analysis plan was pre-registered and published. Following inspection of the data, some changes to the preregistered analysis plan were necessary, outlined here.

- The protocol included a further (eighth) study [COINCIDE (45)] for inclusion in the PREDICTR dataset. The IPD from COINCIDE could not be used in the analysis as there was data only from baseline, 4 months and 24 months and, as a result, we could not define the outcome of relapse within 6-8 months for this study.
- 2. The IPD from REEACT did not use the GAD-7 to measure anxiety. Instead, the authors had used the Clinical Interview Schedule-Revised (CIS-R). Rather than discard the IPD from REEACT, we made the decision to use the anxiety subscale from the CIS-R as a measure of comorbid anxiety. We converted this to standardised scores (z-scores) and used this to model this predictor, along with z-scores for GAD-7 from the other six studies. Z-scores were calculated within each cluster for the whole dataset, prior to removing those who had not reached remission. For the primary analysis, therefore, comorbid anxiety was measured as z-score rather than GAD-7 as planned. To test the validity of this, we conducted a sensitivity analysis removing REEACT from the analysis and using GAD-7 to assess the impact of this decision.
- 3. Given the number of systematically missing exploratory predictors (see Supplemental Table 5), the pre-planned exploratory analysis, using data-driven predictor selection, could not be performed. However, we were able to measure univariable associations between these exploratory predictors and relapse. Where this association was statistically significant, we measured the effect on predictive performance of including the predictor in the model. The Bonferroni method was used to account for multiple significance testing to

14

provide adjusted p-values for use as thresholds for significance. This was done to reduce the risk of false positive significant associations after multiple testing during the exploratory analysis.

- 4. The planned sensitivity analysis omitting WYLOW and COBRA were not deemed necessary as the IECV included a development analysis omitting WYLOW and COBRA (and used these as validation sets).
- 5. The definition of "unemployed" changed from the protocol, prior to any analysis. We adapted the categorisation of employed to include those unemployed but not seeking work due to ill health.

2. Descriptive statistics and risk of bias assessment

Variable				Vari	able present i	n study			Total	Total
		CADET	CASPER	COBRA	Healthlines	REEACT	REEACT-	WYLOW	number	number
		(n=158)	Plus	(n=169)	Depression	(n=221)	2	(n=326)	with	missing
		, ,	(n=101)	· · · ·	(n=110)	· · · · ·	(n=159)	· · · ·	predictor*	(%)
Previous episodes	Available in	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	1244	127
	study?									(10.2)
	Number of	None	None	16	13	None	None	98		
	participants			(9.5)	(11.8)			(30)		
	with									
	missing									
	data (%)									
Residual symptoms	Available in	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	1244	0
	study?									
	Number of	None	None	None	None	None	None	None		
	participants									
	with									
	missing									
	data (%)									
Severity	Available in	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	1244	0
	study?									
	Number of	None	None	None	None	None	None	None		
	participants									
	with									
	missing									
	data (%)									
Comorbid anxiety: GAD-7	Available in	\checkmark	\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	1023	4
	study?									(0.4)
	Number of	2	1	None	1		None	None		
	participants	(1.3)	(1)		(0.9)					
	with									

Table 2.1: Availability of variables and missing data in individual participant data

	missing data (%)									
Comorbid anxiety: CIS-R	Available in		I	I	I	\checkmark		I	221	1
(% missing)	Study? Number of					1				(0.5)
	participants					(0.5)				
	with									
	missing									
Age-continuous	Available in	/	/	/		/		/	1134	1
(% missing)	study?	V	V	V		V	V	V	1101	(0.09)
	Number of	None	None	None		1	None	None		
	participants					(0.5)				
	with									
	data (%)									
Age-categorical	Available in				1		1		110	0
5 5	study?									
	Number of				None					
	participants									
	with									
	missing									
Gender	Qala (%)	/	/		/				1244	0
Gender	study?	\checkmark	V	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	1277	Ū
	Number of	None								
	participants									
	with									
	missing									
Ethnicity					,	,	,		1244	17
	study?	\checkmark	1244	(1.4)						
	Number of	None	None	None	None	None	1	16		()
	participants	NONC			None		(0.6)	(4.9)		
	with						· · ·			

	missing data (%)									
Employment status	Available in study?	\checkmark		\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	1143	2 (0.2)
	Number of participants with missing data (%)	1 (0.6)		None	1 (0.9)	None	None	None		
Relationship status	Available in study?	\checkmark		\checkmark		\checkmark	\checkmark		707	37 (5.2)
	Number of participants with missing data (%)	None		None		36 (16.3)	1 (0.6)			
Multimorbidity	Available in study?	\checkmark	\checkmark	\checkmark				\checkmark	754	33 (4.4)
	Number of participants with missing data (%)	None	None	None				33 (10.1)		
Antidepressant use at remission	Available in study?	\checkmark	\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	1023	49 (4.8)
	Number of participants with missing data (%)	None	18 (17.8)	None	2 (1.8)		26 (16.4)	3 (0.9)		

 $\sqrt{}$ = variable present in study; *Number of participants in the combined studies with predictor available (including those with missing data)

Predictor			Stu	ıdy (total numb	er of participants	in study)		
variable		CADET (n=158)	CASPER Plus (n=101)	COBRA (n=169)	Healthlines Depression (n=110)	REEACT (n=221)	REEACT-2 (n=159)	WYLOW (n=326)
RCT Intervention	Effective RCT Intervention	Collaborative care: n=87	Collaborative care: n=56	CBT: n=92 BA: n=77	Healthlines Integrated Telehealth intervention: n=67	RCT Intervention (cCBT) was not effective	MoodGym with telephone support: n=80	Not applicable. All participants received LiCBT through IAPT.
	Ineffective RCT Intervention or Control	Usual care: n=72	Usual care: n=45	No usual care arm: n=0	Usual care: n=43	cCBT ("Beating the Blues"): n=66; cCBT ("MoodGym"): n=78; Usual care: n=77	Guided self-help with telephone support: n=30; MoodGym only: n=49	
Ethnicity	White	White: n=137	White: n=100	White British: n=155; White Irish: n=4; White (other): n=6	White: n=107	White British: n=208; Any other White background: n=8	White British: n=145; White Irish: n=3; Any other White background: n=6	White: n=292
	Non-white	Asian or Asian British: n=8; Black or Black British: n=7; Mixed: n=3; Other: n=3	Black or Black British: n=1	Other Asian: n=1; Black African: n=1; Other=1; Prefer not to say: n=1	Mixed: n=2; Other: n=1	Asian or Asian British: n=1; Chinese: n=1; Japanese: n=1; Jewish: n=1	Asian or Asian British (Indian): n=1 Chinese: n=1 Other (not specified): n=2	Mixed: n=7; Asian: n=5; Black: n=4; Chinese: n=1; Other: n=2
	Missing	Missing: n=0	Missing: n=0	Missing: n=0	Missing: n=0	Missing: n=0	Missing: n=1	Missing: n=16

Table 2.2: Summary of categorical predictors and their coding in original datasets

Relationship status	In a relationship Not in a relationship	Married/living as married: n=69 Single: n=49; Separated:	Cohabiting: n=19; Civil partnership: n=1; Married: n=86 Single: n=32; Divorced /		Married: n=100; Living with a partner: n=38; In a relationship: n=2 Divorced /	Married: n=71; Living with partner: n=22 Divorced/separat	
	Missing	n=13; Divorced: n=23; Widowed: n=4 Missing: n=0	separated: n=31 Missing: n=0		n=21; Widowed: n=2; Never married: n=22 Missing: n=36	Widowed: n=4; Single: n=39; Other (not specified): n=1 Missing: n=1	
Employment status	Employed or not seeking employment	Full-time paid or self employment: n=66; Part-time paid or self employment: n=29; Voluntary employment: n=1; Student: n=3; Housewife / husband: n=12; Retired: n=13; Other=9	Employed / student: n=120; Retired: n=12	Full time work: n=35; Part time work: n=18; Full time education: n=1; Unable to work (illness): n=15; Unable to work (carer): n=1; Retired: n=20; Looking after home: n=7; Other: n=9	Employed part- time: n=37; Employed full- time: n=92; Self=employed: n=21; Retired: n=14; Looking after family or home: n=9; Not employed (ill health): n=15; Not employed but not seeking: n=3; Other: n=22	Employed part- time: n=26; Employed full- time: n=62; Self-employed: n=15; Retired: n=16; Looking after family or home: n=5; Not employed but not seeking work due to ill health: n=4; Full-time student: n=16; Other (job lined up): n=1	Employed, retired, student, homemaker: n=214

	Unemployed	Unemployed: n=27		Not employed: n=37	Unemployed: n=4	Not employed but seeking work: n=8	Not employed but seeking work: n=10	Unemployed: n=112
	Missing	Missing: n=0		Missing: n=0	Missing: n=1	Missing: n=0	Missing: n=0	Missing: n=0
Multimorbidity	Multi-morbidity	Diabetes: n=2; Asthma: n=14; Arthritis: n=7; Heart disease: n=3; High blood pressure: n=11; More than one of the above: n=11; Other: n=40	At least one of diabetes, osteoporosis, hypertension, rheumatoid arthritis, osteoarthritis, stroke, cancer, respiratory condition, eye condition, or heart disease: n=86	One or more long-term conditions (in addition to depression): n=96				Long-term condition (self- reported): n=87
	No multi- morbidity	No long- standing illness, disability or infirmity: n=70	None of above: n=15	None: n=73				No long-term condition (self- reported): n=206
	Missing	Missing: n=0	Missing: n=0	Missing: n=0				Missing: n=33
Age (categorical)	<40 years old	n=64	n=0	n=59	n=22	n=96	n=68	n=145
	40-49 years old	n=40	n=0	n=46	n=25	n=69	n=39	n=85
	50-59 years old	n=35	n=0	n=37	n=32	n=39	n=24	n=64
	60-69 years old	n=17	n=43	n=18	n=22	n=12	n=25	n=24

70 years and	n=2	n=58	n=9	n=9	n=4	n=3	n=8
over							

ltem	Mean so	ore (SD)*
	REEACT Total	REEACT PREDICTR
	(n=685)	(n=221)
Compulsions	0.72 (1.19)	0.47 (0.97)
Anxiety	2.19 (1.51)	2.01 (1.55)
Irritability	2.16 (1.36)	1.94 (1.38)
Worry	2.46 (1.33)	2.38 (1.38)
Panic	0.74 (1.25)	0.44 (1.03)
Phobias	1.34 (1.28)	1.15 (1.15)
Obsessions	1.26 (1.60)	1.06 (1.49)
Health anxiety	0.88 (1.15)	0.70 (1.03)
Somatic concerns	1.51 (1.44)	1.33 (1.38)
Total	13.27 (6.66)	11.45 5.86)

Table 2.3: Summary statistics for CIS-R anxiety subscale in REEACT

*For REEACT dataset as a whole (REEACT Total) and for those included in PREDICTR study (i.e. those who have remitted) (REEACT PREDICTR):

				Study			
	CADET (Richards et al., 2013)	CASPER Plus (Bosanquet et al., 2017)	COBRA (Richards et al., 2016)	Healthlines Depression (Salisbury et al., 2016)	REEACT (Gilbody et al., 2015)	REEACT-2 (Gilbody et al., 2017)	WYLOW (Ali et al., 2017)
Domain 1: Partic	cipants						
1.1. Appropriate data sources?	Yes	Yes	Yes	Yes	Yes	Yes	Yes
1.2. Appropriate inclusions and exclusion?	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Risk of bias	Low	Low	Low	Low	Low	Low	Low
Domain 2: Predi	ctors						
2.1. Defined and assessed in similar way for all participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes
2.2. Assessments made without knowledge of outcome?	Yes	Yes	Yes	Yes	Yes	Yes	Yes
2.3. All available at	Yes	Yes	Yes	Yes	Yes	Yes	Yes

Table 2.4: Detailed risk of bias assessment (PROBAST) for sources of IPD

time of model's							
intended use?							
Risk of bias	Low						
Domain 3: Outco	ome						
3.1. Determined	Yes						
appropriately?							
3.2. Pre-	Yes						
specified or							
standard							
definition?							
3.3. Predictors	Yes						
excluded from							
outcome							
definition?							
3.4. Defined	Yes						
and determined							
similar for all							
participants?							
3.5. Determined	Yes						
without							
knowledge of							
predictors?							
3.6. Appropriate	Yes						
time interval							
between							
predictor							
assessment							

and outcome							
determination?							
Risk of bias	Low						
Overall	Low						
assessment of							
risk of bias							

3. Model development and apparent performance



Figure 3.1: Distribution of predicted probabilities (apparent performance before shrinkage) by observed outcomes in each cluster

Study	N total	C-statistic	Calibration	Calibration-
	(N	(95% CI)	slope (95%	in-the-large
	relapsed)		CI)	(95% CI)
CADET	158	0.56	0.50	0.01
	(32)	(0.45 to	(-0.34 to	(-0.38 to
		0.67)	1.33)	0.41)
CASPER	101	0.55	0.25	0.53
Plus	(28)	(0.42 to	(-0.73 to	(0.08 to
		0.68)	1.24)	0.97)
COBRA	169	0.64	1.45	-0.63
	(19)	(0.49 to	(0.22 to	(-1.11 to -
		0.79)	2.69)	0.15)
Healthlines	110	0.63	1.35	0.05
Depression	(24)	(0.50 to	(0.01 to	(-0.41 to
		0.76)	2.70)	0.50)
REEACT	221	0.55	0.56	-0.21
	(34)	(0.45 to	(-0.23 to	(-0.58 to
		0.66)	1.34)	0.17)
REEACT-2	159	0.66	1.12	-0.67
	(17)	(0.51 to	(-0.08 to	(-1.18 to -
		0.81)	2.33)	0.16)
WYLOW	326	0.68	1.48	1.00
	(107)	(0.62 to	(0.93 to	(0.76 to
		0.74)	2.03)	1.23)
Pooled	1244	0.62	0.95	0.03
results	(261)	(0.57 to	(0.54 to	(-0.49 to
		0.67)	1.36)	0.54)

Table 3.2: Within-cluster and pooled (apparent) predictive performance statistics for primary analysis model



Figure 3.1: Pooled performance statistics for model development (apparent performance)

Figure 3.1(a): Forest plot showing within-cluster and pooled C-statistic (apparent performance)







Figure 3.1(c): Forest plot showing within-cluster and pooled calibration-inthe-large (apparent performance)

Figure 3.2: Calibration plots (with calibration curves) showing apparent performance of developed model in each cluster





4. Internal-external cross validation (IECV)

Full procedure:

We excluded data from each primary study in turn and developed the risk prediction model in the remaining data, using the same model development approach as detailed (without shrinkage, as the purpose was primarily to explore the generalisability of the model). We then externally validated the developed model using the data from the excluded study. This process was repeated, each time omitting a different study, until the model had been fitted excluding each study once. Predictive performance metrics (C-statistic for discrimination; calibration slope, calibration-in-the-large and visual inspection of calibration plots with LOESS-smoothed calibration curves for calibration) were calculated for the final developed model in each "external" validation (that is, when the model was applied in the study that had been left out). Random effects meta-analysis was used to summarise the performance across studies, to obtain summary measures of the model performance and estimates of heterogeneity in performance across studies. 95% prediction intervals were also constructed to calculate the model's likely performance in new but similar settings.

Random effects meta-analyses were performed to summarise the performance statistics from each validation within each round of IECV. The pooled summary performance statistics are presented in Figure 4.1 and Table 4.1. The distributions of predicted probabilities for each cluster are displayed in Appendix 4.2. Calibration plots were compared for each validation in each of the different clusters (Figure 4.3). These demonstrate inadequate calibration and heterogeneity across clusters (for example, the calibration plot for REEACT-2 demonstrates over-prediction and the one for WYLOW shows under-prediction of outcome).

34



Figure 4.1: Forest plots showing pooled performance statistics for IECV

Figure 4.1(a): Forest plot showing C-statistic for each validation and pooled C-statistic in IECV



Figure 4.1(b): Forest plot showing calibration slope for each validation and pooled calibration slope in IECV



Figure 4.1(c): Forest plot showing CITL for each validation and pooled CITL in IECV

Study	N total	C-statistic	Calibration	Calibration-
	(N	(95% CI)	slope	in-the-large
	relapsed)		(95% CI)	(95% CI)
CADET	158	0.53	0.24	-0.01
	(32)	(0.42 to	(-0.49 to	(-0.41 to
		0.64)	0.96)	0.39)
CASPER	101	0.52	0.13	0.64
Plus	(28)	(0.39 to	(-0.74 to	(0.20 to
		0.65)	1.01)	1.09)
COBRA	169	0.62	1.23	-0.76
	(19)	(0.47 to	(-0.06 to	(-1.24 to
		0.77)	2.51)	-0.28)
Healthlines	110	0.61	1.16	0.04
Depression	(24)	(0.48 to	(-0.22 to	(-0.41 to
		0.75)	2.54)	0.50)
REEACT	221	0.55	0.46	-0.30
	(34)	(0.44 to	(-0.25 to	(-0.67 to
		0.65)	1.18)	0.07)
REEACT-2	159	0.67	1.09	-0.84
	(17)	(0.52 to	(-0.13 to	(-1.35 to
		0.82)	2.31)	-0.33)
WYLOW	326	0.66	1.68	1.13
	(107)	(0.60 to	(1.01 to	(0.89 to
		0.72)	2.36)	1.36)
Pooled	1244	0.60	0.81	0.00
	(261)	(0.55 to	(0.31 to	(-0.61 to
		0.65)	1.31)	0.60)

Table 4.1: Summary of performance statistics in each validation (IECV)



Figure 4.2: Predicted probability distributions in each cluster (IECV)

5) REEACT



7) WYLOW



5. Sensitivity analysis

This sensitivity analysis excluded REEACT and modelled comorbid anxiety as GAD-7 rather than z-score in the other six studies. All other variables and modelling approach were the same as in the primary analysis.

Modelling of continuous predictors

MFPs were used to model continuous predictors and explore non-linear relationships within the imputed datasets, as for the primary analysis.

Table 5.1: Transformations and mean-centring of continuous p	redictors f	following
MFP modelling		

Predictor	Transformation and centring
Residual symptoms	X^2-28.9576543 (X = (residual_symptoms+1))
Residual symptoms 2	X^2*ln(X)-48.73333691 (X = (residual_symptoms+1))
Severity	severity-16.21515152
Comorbid anxiety (GAD-7)	comorbid_anx-12.42807717

(Adjusted) results from the multivariable analysis are presented in Table 5.2.

Predictor	Beta coefficient (95% CI)	p-value
Number of	0.08	0.715
previous episodes	(-0.35 to 0.51)	
Residual	0.15	<0.001
symptoms	(0.09 to 0.22)	
Residual	-0.06	<0.001
symptoms 2	(-0.09 to -0.03	
Severity	0.10	< 0.001
	(0.05 to 0.14)	
Comorbid anxiety	-0.04	0.047
(GAD-7)	(-0.08 to 0.00)	
RCT intervention	0.01	0.979
	(-0.67 to 0.69)	

Table 5.2: Results from multilevel multivariable associations (adjusted*) between outcome and predictors (sensitivity analysis)

Intercept (baseline risk): -1.36 (95% CI: -2.06 to -0.67)

Standard deviation of random effect on intercept: 0.45 (95% CI: 0.12 to 1.72) Standard deviation of random effect on slope (RCT Intervention): 0.54 (95% CI: 0.11 to 2.72)

Correlation between random effects: -0.32 (95% CI: -0.96 to 0.86) *adjusted for other predictor variables within model

We calculated pooled performance statistics (C-statistic, C-slope and calibration-in-the-large) and also within-cluster statistics to assess heterogeneity in model apparent performance during model development. 95% Prediction intervals were also calculated.



Figure 5.1: Pooled performance statistics for sensitivity analysis

Figure 5.1(a): Pooled C-statistic for sensitivity analysis (apparent performance)



Figure 5.1(b): Pooled calibration slope for sensitivity analysis (apparent performance)



Figure 5.1(c): Pooled CITL for sensitivity analysis (apparent performance)

Study	Number in	C-statistic	Calibration	Calibration-
	study	(95% CI)	slope (95%	in-the-large
			CI)	(95% CI)
CADET	158	0.59	0.64	-0.02
		(0.48 to 0.71)	(-0.11 to	(-0.41 to
			1.39)	0.38)
CASPER Plus	101	0.55	0.26	0.36
		(0.42 to 0.68)	(-0.59 to	(-0.09 to
			1.11)	0.80)
COBRA	169	0.64	1.20	-0.66
		(0.49 to 0.79)	(0.19 to	(-1.14 to -
			2.22)	0.18)
Healthlines	110	0.64	1.45	0.05
Depression		(0.52 to 0.77)	(0.18 to	(-0.41 to
			2.73)	0.51)
REEACT-2	159	0.66	1.00	-0.67
		(0.51 to 0.81)	(-0.02 to	(-1.16 to -
			2.01)	0.14)
WYLOW	326	0.69	1.24	1.01
		(0.63 to 0.75)	(0.79 to	(0.77 to 1.25)
			1.69)	
Pooled results	1023	0.65	0.98	0.03
		(0.61 to 0.69)	(0.65 to	(-0.56 to
			1.32)	0.62)

Table 5.3: Summary of within-cluster and pooled apparent performance statistics for sensitivity analysis

6. Secondary analyses

Following the univariable analysis undertaken as part of the secondary analysis, the analysis here explores relationship status as a predictor in the model. The purpose of this exploratory analysis was to assess the impact of including relationship status as a predictor within the model, given its statistically significant association with relapse on univariable analysis. The same modelling procedures were followed as for the primary analysis. We retained a multilevel logistic regression model with random intercept to preserve the clustering, but did not include the random slope due to convergence issues with a lower sample size. There were 707 participants in the four clusters with data available for the relationship status variable (CADET, COBRA, REEACT and REEACT-2). We initially developed the model in this data, without relationship status (Part 1), to enable me to quantify the effect of adding relationship status (Part 2) and provide a like-for-like comparison.

Part 1: Model development without relationship status

Again, MFPs and mean-centring were applied for continuous predictors (Table 6.1).

Table 6.1: Transformation and mean-centring of continuous predictors following MFF	כ
modelling (secondary analysis without relationship status)	

Predictor	Transformation	
Residual symptoms	X residual_symptoms-4.451202263	
Severity	severity-16.53903819	
Comorbid anxiety	comorbid_anx_zscore+.1846512682	

Predictor	Beta coefficient (95% CI)	p-value
Number of	-0.09	0.728
previous episodes	(-0.61 to 0.43)	
Residual	0.08	0.057
symptoms	(0.00 to 0.16)	
Severity	0.08	0.008
	(0.02 to 0.14)	
Comorbid anxiety	-0.14	0.287
	(-0.39 to 0.12)	
RCT intervention	-0.37	0.102
	(-0.81 to 0.07)	

Table 6.2: Multivariable associations (adjusted*) between outcome and predictors for secondary analysis (without relationship status)

Intercept (baseline risk): -1.60 (95% CI: -2.08 to -1.11)

Standard deviation of random effect on intercept: 0.01

* adjusted for other predictor variables within model

I calculated pooled performance statistics (C-statistic, C-slope and calibrationin-the-large) and also within-cluster statistics to assess heterogeneity in model apparent performance during model development. 95% Prediction intervals were also calculated.



Figure 6.1: Pooled performance statistics (secondary analyses)

Figure 6.1(a): Pooled C-statistic (apparent performance) for secondary analysis without relationship status



Figure 6.1(b): Pooled calibration slope (apparent performance) for secondary analysis without relationship status



Figure 6.1(c): Pooled CITL (apparent performance) for secondary analysis without relationship status

Study	Number	C-statistic	Calibration	Calibration-
	in study	(95% CI)	slope (95%	in-the-large
			CI)	(95% CI)
CADET	158	0.59	0.69	0.36
		(0.47 to	(-0.20 to	(-0.04 to
		0.70)	1.57)	0.75)
COBRA	169	0.67	2.03	-0.10
		(0.52 to	(0.53 to	(-0.58 to
		0.81)	3.53)	0.38)
REEACT	221	0.55	0.56	-0.06
		(0.44 to	(-0.37 to	(-0.43 to
		0.67)	1.49)	0.31)
REEACT-2	159	0.64	1.32	-0.27
		(0.48 tp	(-0.03 to	(-0.77 to
		0.80)	2.62)	0.24)
Pooled	707	0.60	0.94	0.01
results		(0.54 to	(0.37 to	(-0.25 to
		0.66)	1.51)	0.27)

Table 6.3: Summary of within-cluster and pooled (apparent) performance statisticsfor secondary analysis without relationship status

Part 2: Multilevel logistic regression model with relationship status

Table 6.4: Transformation and mean-centring of continuous predictors following MFP modelling (secondary analysis with relationship status)

Predictor	Transformation
Residual symptoms	residual_symptoms-4.451202263
Severity	severity-16.53903819
Comorbid anxiety	comorbid_anx_zscore+.1855859548

Table 6.5: Multivariable associations (adjusted) between outcome and predictors for secondary analysis (with relationship status)

Predictor	Coefficient (95% CI)	P value
Number of	-0.15	0.582
previous episodes	(-0.66 to 0.37)	
Residual	0.07	0.081
symptoms	(-0.01 0.15)	
Severity	0.07	0.020
	(0.01 to 0.13)	
Comorbid anxiety	-0.12	0.363
	(-0.37 to 0.14)	
Relationship status	-0.79	0.001
	(-1.23 to -0.34)	
RCT intervention	-0.40	0.076
	(-0.84 to 0.04)	

Intercept (baseline risk): -1.11 (95% CI: -1.65 to -0.56) Standard deviation of random effect on intercept: 2.00e—09 (SE = 155.69)

I calculated pooled performance statistics (C-statistic, C-slope and calibrationin-the-large) and also average within-cluster statistics to assess heterogeneity in model apparent performance during model development. 95% Prediction intervals were also calculated.



Figure 6.2. Pooled performance statistics (secondary analyses)

Figure 6.2(a): Pooled C-statistic (apparent performance) for secondary analysis with relationship status



Figure 6.2(b): Pooled calibration slope (apparent performance) for secondary analysis with relationship status



Figure 6.2(c): Pooled CITL (apparent performance) for secondary analysis with relationship status

Table 6.6: Summary of within-cluster and pooled (apparent) performance statisticsfor secondary analysis with relationship status

Study	Number	C-statistic	Calibration	Calibration-
	in study	(95% CI)	slope (95%	in-the-large
			CI)	(95% CI)
CADET	158	0.63	0.82	0.23
		(0.52-0.73)	(0.13 -	(-0.17 -
			1.51)	0.63)
COBRA	169	0.70	1.64	-0.07
		(0.54-0.85)	(0.61 –	(-0.56 to
			2.67)	0.41)
REEACT	221	0.60	0.72	0.04
		(0.49 –	(0.02 -	(-0.33 to
		0.70)	1.41)	0.41)
REEACT-2	159	0.66	1.08	-0.29
		(0.49 - 0.82)	(0.14 -	(-0.80 to -
			2.01)	0.22)
Pooled	707	0.63	0.96	0.01
results		(0.57-0.70)	(0.56 -	(-0.20 to
			1.36)	0.23)